Two treatments, two different problems

The question most patients arrive with — 'which cartilage injection should I have?' — often rests on a false premise: that ChondroFiller and hyaluronic acid (HA) are competing options for the same problem. They are not. Each targets a distinct diagnosis, and choosing between them begins not with preference but with an MRI.

ChondroFiller is designed for a discrete, full-thickness focal cartilage defect — a defined structural hole in the cartilage surface, graded III or IV on the ICRS/Outerbridge scale. HA viscosupplementation, by contrast, is indicated for mild-to-moderate osteoarthritis, where the primary issue is diffuse joint-surface wear and reduced synovial lubrication across a broad area rather than a single bordered lesion.

Think of it this way: a focal defect is a pothole; widespread osteoarthritis is a road surface that has worn thin. Filling a pothole does not resurface the road, and resurfacing the road does not fill the pothole. The clinical decision axis is diagnosis — confirmed by MRI — not symptom severity. A patient with significant pain but diffuse cartilage thinning is not a candidate for ChondroFiller regardless of how much the pain is limiting them, and a patient with a focal Grade IV lesion will not have that structural gap addressed by HA alone.

In current clinical practice, both treatments are delivered as ultrasound-guided outpatient injections, making the pathway itself comparable. What differs is the mechanism, the indication, and the clinical goal — topics each covered in the sections that follow.

How ChondroFiller works as an injectable scaffold

Structurally, ChondroFiller is a CE-marked Class III medical device — a cell-free hydrogel made from type I collagen derived from murine tissue. It arrives at the clinic as a two-part system that, once mixed, can be placed directly into the focal defect under ultrasound guidance during a standard outpatient appointment. Within three to five minutes of injection, the liquid self-gels in situ, forming a dimensionally stable three-dimensional matrix that physically occupies the lesion.

The mechanism is more sophisticated than simple gap-filling. Once in place, the collagen scaffold draws the patient's own progenitor cells — migrating from the surrounding synovium and subchondral bone — into its structure. This process is known as acellular matrix-induced chondrogenesis: the scaffold itself contains no donor cells, but its architecture and biochemical signals prompt the body's endogenous repair response. Those recruited cells proliferate inside the matrix and begin depositing new cartilage-like repair tissue. Precision of placement matters here; a flush fill is associated with better quality repair tissue, whereas overfilling produces fibrous rather than hyaline-like tissue.

Over the following twelve to twenty-four months, the scaffold is gradually resorbed as the body's own repair tissue consolidates in its place — the temporary framework is replaced by something the patient's biology has built around it.

A 2025 ex vivo osteochondral study provided direct mechanistic confirmation of the cellular recruitment step, documenting a 2.4-fold increase in DNA content within the scaffold by day 14. This is encouraging early laboratory evidence that the scaffold does actively support the body's own repair processes, though translation to individual clinical outcomes depends on defect characteristics and patient factors assessed at the time of consultation.

How hyaluronic acid works as a viscosupplement

Hyaluronic acid occurs naturally in healthy synovial fluid, where it gives the fluid its characteristic viscosity and lubricating properties. In joints affected by osteoarthritis, that fluid thins and loses its cushioning capacity. Intra-articular HA injection — viscosupplementation — replenishes synovial lubrication directly, reducing friction across the joint surface and easing the pain and stiffness associated with mild-to-moderate diffuse OA.

Its primary role is symptomatic. HA does not fill discrete cartilage holes or structurally restore damaged tissue. There is in vitro evidence that HA positively influences chondrocyte growth and matrix production in laboratory conditions, but whether this translates to meaningful structural cartilage regeneration in living arthritic joints remains debated in the literature. Patients and clinicians should treat HA as a symptom-management tool rather than a repair strategy.

Guideline support for viscosupplementation is broadly favourable, though not universal. The 2024 EUROVISCO Delphi consensus — twelve international experts evaluating thirty-four clinical statements — issued strong recommendations for intra-articular HA use in symptomatic knee OA regardless of patient age, and endorsed its use in patients with diabetes, obesity, gout, meniscocalcinosis, and mild-to-moderate joint malalignment. The panel identified active OA flare and pregnancy as the principal contra-indications. Some guidelines, including those from AAOS and ACR, have expressed greater scepticism about the evidence base; patients should discuss current recommendations with their specialist.

Relief typically persists for six to twelve months, so repeat injection courses are common for patients who respond well.

What the clinical evidence shows

Published ChondroFiller outcome data come largely from single-centre prospective series rather than large multicentre trials — context that matters when weighing the numbers below.

In the hip, a cohort of 26 patients followed for three to five years showed that 17 of 21 available patients achieved good or excellent results. Outcomes diverged sharply by joint condition: patients with pre-existing osteoarthritis rated Tönnis grade 2 or 3 fared poorly, reinforcing intact surrounding cartilage as a prerequisite for a favourable result.

Knee data are shorter in follow-up but consistent in direction. A series of 17 patients with a mean age of 31 recorded statistically significant improvement in both Lysholm and IKDC scores at three, six, and 12 months (p<0.05), with scores plateauing between six and 12 months — suggesting durable mid-term stability rather than continued linear gain. An earlier randomised multicentre study comparing ChondroFiller with microfracture documented MRI-confirmed complete defect filling and measurable cartilage maturation by 52 weeks, with no adverse events; high dropout in the microfracture arm limited direct comparison, but the scaffold group's structural signal was clear.

A 2025 wrist study added histological quality data: ChondroFiller-treated defects scored a median Outerbridge grade of 1.5 versus 3.0 in controls (p=0.006; ICRS grade 1 vs 3, p=0.002), extending the evidence across joint types.

Across these series, roughly 70–85% of patients sustain meaningful symptom relief for three to five years from a single course. Viscosupplementation typically provides benefit for six to twelve months, after which repeat injection is needed. No structural outcome dataset comparable to the scaffold series exists for HA alone, and no head-to-head randomised trial has yet compared the two approaches directly — the most significant gap remaining in the evidence.

Suitability, limitations and access

Deciding which treatment to explore depends first on what the imaging shows.

ChondroFiller is appropriate for patients with an MRI-confirmed focal, full-thickness cartilage defect — typically ICRS or Outerbridge Grade III or IV — that is discrete, well-bordered, and surrounded by structurally sound tissue. Diffuse, multi-area wear is outside the scope of a scaffold approach, regardless of symptom severity. Expectations matter too: the goal is hyaline-like repair tissue, not native articular cartilage, and your specialist should discuss the distinction at assessment.

The clearest poor-prognostic factor in the evidence is background joint disease. The hip cohort data — 26 patients followed for three to five years — showed poor outcomes in every patient with pre-existing osteoarthritis rated Tönnis grade 2 or 3. The surrounding joint environment, not just the focal lesion, determines whether the scaffold can support meaningful regeneration; a thorough joint assessment is therefore part of any ChondroFiller workup.

A practical post-procedure point deserves emphasis: a biomechanical in-vitro study found that the freshly placed gel does not reduce loading stress on the opposing cartilage surface during full weight-bearing, owing to the scaffold's initial mechanical instability. Post-procedure weight-bearing restrictions exist for this reason and are clinically important to the repair process, not merely precautionary.

On access, ChondroFiller is CE-marked and used across Europe but is not FDA-approved and is not available through the NHS. In the UK it is offered on a self-funded basis through private specialist clinics; published guide costs range from approximately £3,000 for a single-defect case to around £9,800 for more complex presentations, and current pricing should be confirmed directly with the treating clinic.

Hyaluronic acid is the appropriate pathway for patients with diffuse mild-to-moderate osteoarthritis seeking symptom control. It is widely accessible across both NHS and private settings. The 2024 EUROVISCO consensus identified active joint flare and pregnancy as the main contra-indications; most other common comorbidities — including diabetes, obesity, and mild-to-moderate malalignment — are not barriers to its use.

Finding the right specialist in the UK

The single most useful thing to bring to a first appointment is an MRI report — or, if one has not yet been arranged, a clear request for one. Whether a patient ends up on a scaffold injection pathway or a viscosupplementation course depends almost entirely on what that scan shows, and arriving without imaging means the consultation is partly spent deciding what imaging to do rather than what to do next.

Three questions tend to clarify the pathway quickly once the scan is in hand:

• Has imaging confirmed a focal, full-thickness defect, or is there broader joint degeneration across the surface?
• Based on those findings, is ChondroFiller, HA, or a staged combination the most appropriate next step?
• What does the post-injection recovery period involve, and when can normal loading and activity resume?

Search MSK lists specialists across the UK who offer ChondroFiller injection and HA viscosupplementation — filter by region and specialty to find a clinician with the cartilage-assessment experience your situation requires. If the MRI has not yet been arranged, that is the right place to start.